Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers.

Next Previous
Trial Profile

A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATL 1102 (Primary) ; Granulocyte colony-stimulating factors
  • Indications Stem cell mobilisation
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Antisense Therapeutics; Percheron Therapeutics

Most Recent Events

  • 01 Dec 2023 According to a Percheron Therapeutics media release, the Antisense Therapeutics is now called Percheron Therapeutics.
  • 23 Jul 2014 Results published in the Media Release.
  • 23 Jul 2014 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top